http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#Head http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion http://purl.obolibrary.org/obo/DOID_2377 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2377 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00108 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association http://www.w3.org/2000/01/rdf-schema#label tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1 1 5 1 crohn s disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a 1 2 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnf a 1 2 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 5 1 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a tysabri should not be used in combination with immunosuppressants e g 6 mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnf a see warnings and precautions 5 1 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00108 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig http://purl.org/nanopub/x/hasSignature Ybo5naNNuodmPHxEiH+7ce12zhztxiN+LgdRRPGU4Ozccij6MJANLZQ7exrPZxkZB/5I4ce6KQwK1GZ9/qzQHSMQXRNVS5IOfImoF9FkkGbs5qJx7TJpMBhOxdpqu0nGKRLGUdaB6yokD+ybGnZN6FG6JKm+RNKlOcILXs5rHNI= http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://purl.org/dc/terms/created 2021-07-03T15:13:05.636+02:00 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs